Chimeric Antigen Receptor T-Cells: The Future Is Now
AbstractThe immune system acting via cancer immune-surveillance is considered a potential target for improving outcomes among some malignancies. The ability to harness immune cells, engineer them and educate them to target cancer cells has changed the paradigm for treating non-Hodgkin’s lymphomas (NHL) and acute lymphoblastic leukemia (ALL). Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable anti-tumor activity against refractory B cell malignancies. Ongoing research aims to expand the scope of this adoptive cell therapy, understanding mechanisms of resistance and reducing toxicity. In this review, we will discuss the current scope of CAR T-cell therapy and ongoing future applications. View Full-Text
Share & Cite This Article
Mchayleh, W.; Bedi, P.; Sehgal, R.; Solh, M. Chimeric Antigen Receptor T-Cells: The Future Is Now. J. Clin. Med. 2019, 8, 207.
Mchayleh W, Bedi P, Sehgal R, Solh M. Chimeric Antigen Receptor T-Cells: The Future Is Now. Journal of Clinical Medicine. 2019; 8(2):207.Chicago/Turabian Style
Mchayleh, Wassim; Bedi, Prabhjot; Sehgal, Rajesh; Solh, Melhem. 2019. "Chimeric Antigen Receptor T-Cells: The Future Is Now." J. Clin. Med. 8, no. 2: 207.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.